This trial has completed recruitment on this platform, and is no longer accepting new referrals.
The purpose of the Trio P101 Trial is to assess the safety of and immune responses to investigational vaccines aimed at preventing illness due to 3 common viruses: flu, RSV, and COVID-19 in adults 50 to 75 years of age. Flu, RSV, and COVID-19 are all respiratory illnesses. Flu is caused by the influenza virus. COVID-19 is caused by the SARS-CoV-2 virus. You may be less familiar with RSV, which is one of the most common causes of lower respiratory tract infections worldwide. In this trial, 5 different investigational vaccines will be evaluated. All participants will be randomly assigned to one of the groups in the trial, which will determine which investigational vaccine and dose each participant receives. Each participant will only receive 1 investigational vaccine. In this clinical trial, the investigational vaccines are:
Sites are located in the cities/states identified with the red pin:
Participation in the Trio P101 Trial will last approximately 13 months and includes 7 visits to a trial site and up to 8 safety phone calls. Participants will be given 1 injection of an investigational vaccine in the upper arm.
Participants will use an electronic diary (eDiary) through an app on their smartphone or a provided device, to record how they are feeling for 7 days after they receive the investigational vaccine. Participants will have follow-up visits at their clinical trial site over the course of the trial for tests that will show if the investigational vaccine is working.
Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.